

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



AOM International

AOM INTERNATIONAL GROUP COMPANY LIMITED

權識國際集團股份有限公司

(Incorporated in the Cayman Islands with limited liability and continued in Bermuda with limited liability)

(Stock Code: 00381)

SUPPLEMENTAL ANNOUNCEMENT TO 2024 ANNUAL REPORT

References are made to the annual report of AOM International Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) the Company for the year ended 31 December 2024 (the “**2024 Annual Report**”). Unless otherwise stated, terms used in this announcement shall have the same meanings as those defined in the 2024 Annual Report. This announcement is made to provide supplementary information to the 2024 Annual Report.

USE OF PROCEEDS

As disclosed in the 2024 Annual Report, the Company completed the placement of convertible bonds in the aggregate principal amount of HK\$45,000,000 on 6 February 2024. The net proceeds from the Placing are approximately HK\$44,500,000 and will be applied as to (i) approximately HK\$30,000,000 for the construction of traditional Chinese medicinal herbs plantation base in Hubei; (ii) approximately HK\$10,000,000 for the setting up of a new TCM decoction pieces production lines; and (iii) the remaining of the net proceeds in the approximate amount of HK\$4,500,000 for general working capital of the Group.

On 30 September 2024, the Company completed the placement of 470,000,000 ordinary shares. The net proceeds from the Placing, after deduction of the placing commission and other related expenses, amounted to approximately HK\$51,300,000.

On 17 May 2024, the Company issued and allotted 19,350,000 ordinary shares to a creditor in settlement of the amount due to her of approximately HK\$19,200,000 which was included in other loan. In addition, on 10 October 2024, the Company issued and allotted 53,220,754 ordinary shares to a creditor in settlement of the amount due to her of approximately HK\$7,980,000 which was included in other loan.

In addition to the information disclosed in the 2024 Annual Report, the Board would like to provide supplemental information regarding the actual and intended use of proceeds from the issuance pursuant to paragraph 11(8) of Appendix 16 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Details of the use of proceeds as at 31 December 2024 are as follows:

Date of announcement	Event	Net proceeds raised	Intended use of proceeds	Actual use of proceeds	Proceeds balance as at 31 December 2024 (Note)
2 October 2024 (completed on 10 October 2024)	Issue of new shares under general mandate	Approximately HK\$7,980,000	For loan capitalisation	Used as intended	Nil
3 May 2024 (completed on 17 May 2024)	Issue of new shares under general mandate	Approximately HK\$2,515,000	For loan capitalisation	Used as intended	Nil
16 July 2024 (completed on 30 September 2024)	Placing of new shares under specific mandate	Approximately HK\$51,300,000	(i) HK\$51,000,000 will be utilised to repay the outstanding amount of the First Hubei CB in full; and (ii) HK\$300,000 for general working capital of the Company.	Used as intended	Nil
29 August 2023 (completed on 6 February 2024)	Placing of convertible bonds under specific mandate	Approximately HK\$44,500,000	(i) Approximately HK\$30,000,000 for the construction of Chinese medicinal herbs plantation base in Hubei; (ii) Approximately HK\$10,000,000 for the setting up of a new TCM decoction pieces production lines; and (iii) The remaining of the net proceeds in the approximate amount of HK\$4,500,000 for general working capital of the Group.	Used as intended	Nil

Note:

The net proceeds have been fully utilised during the year 2024.

Details of the use of proceeds as at 31 December 2023 are as follows:

Date of announcement	Event	Net proceeds raised	Intended use of proceeds	Actual use of proceeds	Proceeds balance as at 31 December 2023 (Note)
9 June 2023 (completed on 23 June 2023)	Issue of new shares under general mandate	Approximately HK\$1,842,000	For loan capitalisation	Used as intended	Nil

Note:

The net proceeds have been fully utilised during the year 2023.

The Board confirmed that the supplemental information provided in this announcement does not affect any other information contained in the 2024 Annual Report and, save as disclosed above, the content of the 2024 Annual Report remains unchanged.

By order of the Board
AOM International Group Company Limited
Yang Ling
Chairman

Hong Kong, 18 December 2025

As at the date of this announcement, the Board comprises five executive Directors, Mr. Yang Ling, Mr. Li Lizhong, Mr. Liu Mingqing, Mr. Yang Bincheng and Mr. Fan Xuefei; one non-executive Director Mr. Tang Sing Hing, Kenny; and three independent non-executive Directors, Mr. Chak Ching Long, Mr. Wang Xiao Ning and Ms. Chen Yuxin.